A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis

Project Details

StatusActive
Effective start/end date19/09/2226/09/25

Funding

  • Boehringer Ingelheim Pty Ltd: A$15,000.00
  • Boehringer Ingelheim Pty Ltd: A$25,000.00
  • Boehringer Ingelheim Pty Ltd: A$25,000.00
  • Boehringer Ingelheim Pty Ltd: A$6,000.00